Information & Referral

If you have come to our site seeking information, guidance, or referral services for yourself or another person, you have come to the right place. Wellspring is here to provide education and support to those who need assistance confronting the disease of alcoholism and drug dependence.

Information & Referral

addiction-treatment
Treatment Referrals
Suffering from an addiction problem? We can help you find a treatment facility. You can either browse through our local Treatment Directory, allow us to make suggested referrals by using our self-administered Screening Tool, or if you prefer speaking with one of our professionals, call our confidential Referral Helpline. We are available Monday through Friday from 8 a.m. to 9 p.m. You can also contact us via email at mail@wellspringprevention.org. While not intended to diagnose a substance abuse problem, each of these options will help narrow your search for a program that best meets your needs. Note that the options provided do not represent an exhaustive list of all available programs or constitute an endorsement of particular programs. However, these are programs we have worked with and have consistently received positive feedback from those who have accessed their services. If you live outside of Middlesex County New Jersey, you can get help now by calling the New Jersey Addiction Services Hotline anytime at 844-276-2777. You can also access the New Jersey Mental Health Cares Information and Referral Helpline at 1-866-202-HELP (4357).
If you live outside of New Jersey, reach out to the National Council on Alcoholism and Drug Dependence at www.ncadd.org or 212-269-7797 to find your nearest local resources.
jason-surks-memorial
Jason Surks Memorial Resource Center
The Jason Surks Memorial Prevention Resource Center at Wellspring serves as a clearinghouse for free information about alcohol, tobacco and other drugs. Explore our vast collection of online information and helpful links, or visit us at our East Brunswick, NJ location to access free pamphlets, posters and DVD lending library.
More than just a physical and web-based library, our Resource Center is people. If you need assistance planning an educational program, need information for a health fair, or would like to contract with our staff to provide presentations in your community, please call us at 732-254-3344 or send us an email request at info@wellspringprevention.org.

FDA Should Add “Black Box” Warning to Opioids and Benzodiazepines

image

Officials from state and local health departments around the country are urging the Food and Drug Administration (FDA) to add “black box” warnings to opioid painkillers and sedatives known as benzodiazepines, to alert people that taking them together increases the risk of fatal overdoses.

Recently, health officials submitted a petition to the FDA about the warnings, The Washington Post reports.

The petition urges the FDA to adopt labeling for all opioid medications that reads: “Warning: Concurrent use with benzodiazepines reduces the margin of safety for respiratory depression and contributes to the risk of fatal overdose, particularly in the setting of misuse.” A similar warning would be placed on benzodiazepines, warning about mixing the drugs with opioids.

“Existing warnings about the concurrent use of opioids and benzodiazepines are inconsistent, infrequent, and insufficient. The FDA should act swiftly on the clear scientific evidence and add black box warnings to both classes of medication,” one of the petition’s signers, Dr. Nicole Alexander-Scott, Director of Rhode Island’s Department of Health, said in a news release. “All of us–federal regulators, public health officials, and healthcare providers–have moral and professional obligations to make sure that people stop dying because of these drugs.”

The officials noted patients with chronic pain are often prescribed opioids to treat their pain and benzodiazepines to treat their associated symptoms, such as anxiety and sleep disorders. They said taken together, the two classes of drugs can severely depress the respiratory system, causing the patient to stop breathing.

The FDA said in a statement that it “is committed to working with the health care community and our federal, state and local partners to help reduce opioid and benzodiazepine misuse and abuse. We will continue to monitor the combined use of these products and take necessary actions to ensure prescribers and the public are informed of the risks involved with the use of these medications.”

Log in

fb iconLog in with Facebook
create an account